REPL

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024 (GLOB...

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies,...

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics li...

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionab...

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.